Impact of critical illness on continuation of anticancer treatment and prognosis of patients with aggressive hematological malignancies.

ABSTRACT:

Background

Maintaining the dose-intensity of cancer treatment is an important prognostic factor of aggressive hematological malignancies. The objective of this study was to assess the long-term outcomes of intensive care unit (ICU) survivors with acute myeloid leukemia (AML) or aggressive B-cell non-Hodgkin lymphoma (B-NHL) with emphasis on the resumption of the intended optimal regimen of cancer treatment.

Patients and methods

We conducted a retrospective (2013-2021) single-center observational study where we included patients with AML and B-NHL discharged alive from the ICU after an unplanned admission. The primary endpoint was the change in the intended optimal cancer treatment following ICU discharge. Secondary endpoints were 1-year progression-free survival and overall

SUBMITTER: Bredin S 

PROVIDER: S-EPMC11390996 | biostudies-literature | 2024 Sep

REPOSITORIES: biostudies-literature